Last update 23 Jan 2025

Nanjing Ruikewei Biomedical Co. Ltd.

Startups
|
Subsidiary Company|
2016|
Jiangsu Sheng, China
|
www.njrkw.com

Overview

Tags

Cardiovascular Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
A2aR(Adenosine A2a receptor)1

Related

1
Drugs associated with Nanjing Ruikewei Biomedical Co. Ltd.
Regadenoson
Target
A2aR
Mechanism
A2aR agonists
Active Org.
Nanjing Ruikewei Biomedical Co. Ltd.Startup [+5]
Originator Org.
Astellas Pharma, Inc.Astellas Pharma, Inc.
Active Indication
Heart Diseases [+4]
Inactive Indication
Anemia, Sickle Cell [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date10 Apr 2008
1
Clinical Trials associated with Nanjing Ruikewei Biomedical Co. Ltd.
CTR20231854
/ RecruitingPhase 3
瑞加诺生注射液用于负荷超声心动图试验诊断冠心病的多中心、随机、自身对照、阳性药对照的Ⅲ期临床研究
[Translation] A multicenter, randomized, self-controlled, positive drug-controlled phase III clinical study of Reganosane injection for the diagnosis of coronary heart disease in stress echocardiography
100 Clinical Results associated with Nanjing Ruikewei Biomedical Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Nanjing Ruikewei Biomedical Co. Ltd.
Login to view more data
100 Deals associated with Nanjing Ruikewei Biomedical Co. Ltd.
Login to view more data
100 Translational Medicine associated with Nanjing Ruikewei Biomedical Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Regadenoson
 ( A2aR )		Heart Diseases
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free